Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Undervalued vs peers
About
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/
Target Price
The average target price of BHC is 6.8 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell